InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Provides Update on Market, Product Development of Key Biosensor

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released a market and product development report. The report focused on XPhyto’s sublingual oral dissolvable film (“ODF”) biosensor development pipeline, which include the company’s oral dissolvable products. These products are based on proprietary ODF platform technology developed by XPhyto’s wholly owned German subsidiary, Vektor Pharma TF GmbH, which is a German drug manufacturer, developer and research organization. According to the announcement, the products also incorporate proprietary biosensor molecules developed by XPhyto’s recently acquired and wholly owned Germany subsidiary, 3a-diagnostics GmbH (“3a”), an innovative medical diagnostics developer. 3a is working on developing rapid point-of-care pathogen screening tests; the company currently has a pipeline of biosensor screening products for bacterial and viral infectious diseases, including stomatitis, periimplantitis, periodontitis, group A strep and influenza A. By combining key technologies from Vektor and 3a technologies, XPhyto has created a promising pipeline of rapid screening test products with near-term commercialization potential.

To view the full press release, visit https://ibn.fm/3jYjz

About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and the manufacture, standardization and evaluation of psychedelic compounds for the treatment of neurological conditions. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.